Duvelisib is a medication used in this clinical trial to treat patients with a type of blood cancer called nodal T cell lymphoma. It works by blocking certain proteins in the body that help cancer cells grow and survive. By doing this, duvelisib can help slow down or stop the progression of the cancer.

Gemcitabine is another medication used in this trial. It is a type of chemotherapy that helps to kill cancer cells. Gemcitabine works by interfering with the DNA of the cancer cells, preventing them from multiplying and spreading. This can help reduce the size of the cancer and control its growth.

Bendamustine is also used in this study as a treatment option. It is a chemotherapy drug that attacks cancer cells by damaging their DNA, which stops them from dividing and growing. Bendamustine is used to help manage and reduce the symptoms of the cancer, aiming to improve the patient’s quality of life.

Relapsed/Refractory Nodal T Cell Lymphoma with T Follicular Helper (TFH) Phenotype – This is a type of non-Hodgkin lymphoma that originates from T cells, a kind of white blood cell. It specifically involves the T follicular helper cells, which are crucial for the immune system’s response. The disease is characterized by the recurrence or persistence of lymphoma after initial treatment. It typically presents with enlarged lymph nodes and can affect other organs. As the disease progresses, it may lead to symptoms such as fatigue, fever, and weight loss. The progression involves the continued growth and spread of cancerous cells in the lymphatic system.